Impaired cell death program has been noted as one of the hallmarks of chronic lymphocytic leukemia (CLL) and contributes to its accumulation of malignant monoclonal B cells as well as to chemotherapy resistance. A cell can die through the apoptosis or necrosis pathway. Recent investigations suggest that in apoptotic-deficient conditions, such as most types of cancer, a process of programmed necrosis, called necroptosis, prevails. However, the detailed molecular mechanisms underlying this alternative cell death pathway are still not fully understood. Here we demonstrate that CLL cells failed to undergo necroptosis upon stimulation of TNFa combined with pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD). Two core components of necroptotic machine, RIP3 and deubiquitinase cylindromatosis (CYLD), are markedly downregulated in CLL. Moreover, we identified lymphoid enhancer-binding factor 1 (LEF1), a downstream effector of the Wnt/b-catenin pathway, as a transcription repressor of CYLD in CLL. Knocking down LEF1 sensitizes CLL cells to TNFa/zVAD-induced necroptosis. The present investigation provides the first evidence that CLL cells have defects not only in apoptotic program but also in necroptotic signaling. Targeting the key regulators of necroptotic machine, such as LEF1, to restore this pathway may represent a novel approach for CLL treatment.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most prevalent form of adult leukemia in the Western world characterized by the accumulation of small B lymphocytes that have a mature appearance. Worldwide, there is a considerable variability in CLL incidence, with low incidences in Asia and Africa. 1, 2 The progressive accumulation of monoclonal B lymphocytes leads to leukocytosis, lymphadenopathy, hepatosplenomegaly, bone-marrow failure, recurrent infection and is sometimes associated with autoimmune disease. 1 This accumulation has been largely attributed to defective apoptosis programs rather than excessive cellular proliferation. Several mechanisms could account for the resistance of CLL cells to apoptosis. Genetic or epigenetic modifications can result in intrinsic defects in apoptotic machinery. Moreover, interactions of leukemic cells with their microenvironment may enhance the resistance to programmed cell death. 3 --5 A cell can die through the apoptosis or necrosis pathway. 6 Although apoptosis is known as a regulated cellular program, necrosis is known as an accidental event caused by overwhelming stress. 7 However, accumulating evidence suggests that necrosis can also be executed by regulated mechanisms, especially in apoptotic-deficient conditions. 6 --9 Recently, the term necroptosis has been used to designate one particular form of programmed necrosis induced by stimulating death receptors with agonists such as TNFa, FasL and TRAIL. 6, 7 Apoptosis suppression by caspase inhibitors, such as benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD), may switch apoptotic response to necroptosis or enhance necroptosis. The kinase activity of receptor-interacting protein 1 (RIP1) is crucial for this alternative pathway triggered by death receptor ligation. Reactive oxygen species (ROS) derived from mitochondria are also required for necroptosis in response to death-inducing cytokines. Moreover, Necrostatin-1 (Nec-1) has been identified as a specific chemical inhibitor of necroptotic pathway. 10 Necroptotic cell death is considered to serve two functions in vivo. 6 First, it acts as a backup mechanism to kill virus-infected cells if apoptotic pathway is blocked. Second, necroptosis may promote the release of intracellular danger-associated molecular patterns, which acts as endogenous adjuvants that boost the innate immune response. However, with respect to the significance of necroptosis in malignant disease, much less is known.
In contrast to the well-characterized apoptotic pathway, the detailed molecular mechanisms underlying necroptosis are still not fully understood. Recent investigations have identified several key regulators of this form of programmed cell death. 6 --9 The deubiquitinase cylindromatosis (CYLD) is recruited to the TNFa receptor upon its activation and directly regulates RIP1 ubiquitination. CYLD gene silencing suppresses TNFa-induced necroptosis in cultured human Jurkat cells lacking apoptotic factor Fas-associated death domain. A genome-wide small interfering RNA (siRNA) screen revealed another member of the RIP kinase family, protein kinase RIP3, to be essential for necroptosis. Upon stimulation of death receptors, RIP3 is recruited to RIP1 to form a necroptosis-inducing complex, which is essential for cell death execution. In addition, by activating key enzymes of the metabolic pathways, RIP3 regulates TNFa-inducing ROS production, which partly accounts for its ability to potentiate necroptosis. 9 In the present study, we describe for the first time the defective necroptotic signaling in CLL, as highlighted by an impaired necroptotic response induced by death receptor ligation as well as downregulation of two core regulators of the necroptotic pathway, RIP3 and CYLD. In addition, we identified lymphoid enhancer-binding factor 1 (LEF1) as a transcription repressor of CYLD in CLL. We also determined the effect of targeting LEF1 to upregulate CYLD on mitochondrial ROS production and necroptotic cell death in this disease.
MATERIALS AND METHODS

Cell culture and reagents
Peripheral blood samples were obtained from CLL patients and healthy volunteers following informed consent obtained in accordance with the Declaration of Helsinki, and with approval obtained from the institutional review board of the First Affiliated Hospital of Nanjing Medical University (Nanjing, PR China) for these studies. All patients had immunophenotypically defined CLL according to the WHO classification. Mononuclear cells were isolated from the blood samples by Ficoll-isopaque centrifugation and the B lymphocytes were purified from this fraction by immunomagnetic separation using CD19 microbeads (Miltenyi Biotec, Auburn, CA, USA). Flow-cytometric analysis revealed that at least 95% of either the normal or the CLL cells in the purified B-cell fractions were CD19 positive but negative for the T-cell antigen CD3. 293T cell line was obtained from the American Type Culture Collection. The cells were resuspended in RPMI 1640 (for normal or malignant B cells) or DMEM medium (for 293T cells) supplemented with 10% heat-inactivated fetal bovine serum in a 5% CO 2 -humidified atmosphere at 37 1C. TNFa was purchased from Sigma (St Louis, MO, USA). Nec-1 and zVAD were purchased from Alexis Biochemicals (San Diego, CA, USA).
Western blot
Whole-cell pellets were lysed in 50 mM Tris-HCl (pH 7.6) buffer containing 0.15 M NaCl, 1 mM EDTA, 10 mg/ml leupeptin and benzamidine, 1 mM PMSF and 1% Triton X-100. Proteins in cell lysates were resolved by SDSpolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). Membranes were blocked in bovine serum albumin (3%) in Tris-buffered saline --Tween 20 (0.05%) and incubated with antibodies against human RIP1 (BD Biosciences, San Jose, CA, USA), CYLD (Abcam Inc., Cambridge, MA, USA), LEF1 (Cell Signaling Technology, Beverly, MA, USA, C18A7, Catalog no. 2286), T-cell factor 4 (TCF4) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and b-catenin (Cell Signaling Technology) at 1:1000 dilutions followed by horseradish peroxidase --conjugated secondary antibodies at 1:5000 dilutions. Detection was performed by using enhanced chemiluminescence.
Quantitative real-time reverse transcription-PCR Total RNA was extracted from cells using Trizol (Invitrogen, San Diego, CA, USA) and treated with DNaseI (Ambion, Austin, TX, USA). In all, 1 mg of total RNA was used for first-strand DNA synthesis using iScript cDNA Synthesis system (Bio-Rad). Real-Time PCR was performed using iQ SYBR Green Supermix and the iCycler Real-Time PCR Detection System (Bio-Rad). Each sample was run in triplicate. The relative RNA amounts were calculated with the DDCt method and normalized with an internal control, 18s rRNA. The sequences of primers used are available upon request.
Plasmid constructions
A promoter construct encompassing the region À1995 to À41 bp relative to the transcription start site of the human CYLD gene was amplified from human genomic DNA using primers containing KpnI and XhoI restriction sites and cloned into pGL3-Basic (Promega, Madison, WI, USA). The resultant plasmid was designated as pCYLD-LUC. Mutations were introduced into two different LEF1 responsive elements in pCYLD-LUC using the QuikChange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The expression plasmids of LEF1, dominant-negative LEF1 (ref. 11) (a short isoform of LEF1 that lacks the b-catenin-binding domain), b-catenin and another TCF-family member TCF4 were constructed by cloning human cDNA of gene of interest into pcDNA3.1 (Invitrogen) with PCR primers containing appropriate restriction sites. The details of primer sequences used for the amplification of constructs are available upon request. The nucleotide sequences were confirmed by restriction digestion and sequencing.
Luciferase reporter assays 293T cells were transfected with reporter constructs mentioned above by using Lipofectamine LTX Reagent (Invitrogen). A Renilla luciferase plasmid (pRL-SV40 from Promega) was co-transfected as an internal control. Cells were harvested 48 h after transfection, and the luciferase activities of the cell lysates were measured by using the Dual-luciferase Reporter Assay System (Promega).
Chromatin immunoprecipitation (ChIP) assay Cells were crosslinked with 1% formaldehyde for 10 min at room temperature, and formaldehyde was then inactivated by the addition of 125 mM glycine. Chromatin extracts containing DNA fragments were immunoprecipitated by using the antibodies against LEF1 (Cell Signaling Technology, C18A7, Catalog no. 2286). The immunoprecipitated chromatin was amplified using sets of primers (available upon request) flanking each LEF1-binding site within CYLD promoter. All ChIP experiments were repeated at least three times. 
Detection of ROS accumulation
Mitochondrial ROS production was measured as described. 9 Cells were treated with different stimuli for the indicated time periods. CM-H2DCFDA (5 mM) was added 30 min before collecting cells. The stained cells were analyzed with a flow cytometer. Results were processed using CellQuest program (BD Biosciences, San Jose, CA, USA).
Cell survival determination
Measurement of cell survival was performed as described. 9 Cell death was determined by flow cytometry with two parameters: plasma membrane integrity and cell size. The plasma membrane integrity was tested by the ability of cells to exclude propidium iodide (Sigma). Cells were collected by centrifugation, washed once with phosphate-buffered saline and resuspended in phosphate-buffered saline containing 5 mg/ml propidium iodide. The levels of propidium iodide incorporation were quantified on a FACScan flow cytometer (Beckman Coulter, Fullerton, CA, USA). Cell size was evaluated by forward-angle light scattering. Propidium iodide negative cells with a normal size were considered living.
Electron microscopy
Cells were washed once in phosphate-buffered saline and fixed for 30 min in 2.5%. glutaraldehyde in 0.1 mol/l sodium phosphate buffer (pH 7.4). The samples were then treated with 1.5% osmium tetroxide, dehydrated with acetone and embedded in durcupan resin. Thin sections were post-stained with lead citrate and examined in the TECNAI 10 electron microscope (Philips, Amsterdam, the Netherlands) at 60 kV.
Statistical analysis
Data are presented as mean±s.d. of at least three independent experiments. Differences between groups were analyzed using two-tailed Student's t-test. Po0.05 was considered statistically significant.
RESULTS
Defective necroptotic response to TNFa treatment in CLL
We first compared the TNFa-induced necroptosis between normal CD19 þ B cells and CLL samples. Cells were treated with DMSO, a pan-caspase inhibitor zVAD (20 mM), Nec-1 (30 mM), TNFa (30 ng/ml), and TNFa plus zVAD with or without Nec-1 for 24 h. Cell survival was measured as described in Materials and methods. As shown in Figure 1a , for normal B cells, TNFa treatment led to an increase in cell death (Po0.001) and zVAD had no effect on cell survival (P40.05). Interestingly, zVAD incubation dramatically sensitized normal B cells to TNFa-induced cell death (Po0.001), which was effectively inhibited by Nec-1 treatment (Po0.001). Consistent with a previous report, our data indicated that caspase inhibition, which distinguishes apoptotic and non-apoptotic cell death, can drive cells to use necroptosis as an alternative cell death pathway and potentiate the necroptotic response induced by death receptor ligation.
7 --9 However, we could not find any synergistic effect between TNFa and zVAD in triggering CLL cell death (P40.05). Actually, CLL cells were resistant to all the regimens (TNFa, zVAD, and TNFa plus zVAD with or without Nec-1) mentioned above, indicating there are defects in the necroptotic pathway in this disease.
As mitochondrial generation of ROS is required for TNFa-or TNFa þ zVAD-induced necroptosis in L929 cells, mouse embryonic fibroblasts and macrophages, 6 --9,12,13 we then tested the ability of CLL cells to produce ROS in response to necroptotic cell death inducer. As shown in Figure 1b , upon TNFa þ zVAD stimulation, normal CD19 þ B cells increased ROS production 49-fold. The ROS induction by TNFa þ zVAD was significantly inhibited following Nec-1 treatment. However, TNFa þ zVAD incubation only resulted in B2-fold induction in ROS generation in CLL samples.
To verify that the cell death induced by TNFa þ zVAD was indeed necroptosis, we also performed electron microscopy analysis. As shown in Supplementary Figure S1 , most DMSOtreated normal B cells showed normal cellular morphology including intact plasma membranes. TNFa þ zVAD treatment resulted in a dramatic increase in number of cells showing necroptotic morphology, including membrane breakdown and numerous swollen cellular organelles in normal B cells. Furthermore, this necroptosis induction could be significantly inhibited by Nec-1 treatment. Consistent with the results described in Figure 1a , there is no change in necroptotic cell death among CLL sample treated with DMSO, TNFa, or TNFa plus zVAD.
Loss of core components of necroptotic machine in CLL Genome-wide siRNA screen has identified several key regulators required for necroptosis including RIP1, RIP3 and CYLD. 7 --9 We then examine the expression profile of these three core components of the necroptotic pathway in CLL cells. Figure 2 shows western blot and real-time reverse transcription-PCR results in 9 normal CD19 þ B cells and 18 CLL samples. There is no difference in RIP1 levels between healthy controls and CLL cells. However, CYLD are markedly downregulated in CLL compared with normal B cells at both protein and transcription levels (Po0.001). Moreover, the expression of another key necroptotic machine component measured in this study, RIP3, is also suppressed in CLL patients in comparison with healthy subjects, which was confirmed using quantitative real-time reverse transcription-PCR (Po0.001). Unfortunately, we were unable to evaluate protein levels of this molecule as currently available antibodies were inadequate for immunoblot analysis.
LEF1 acts as a transcription repressor of CYLD in CLL Through enhancement analysis of cis regulatory elements, Hitomi et al. 7 identified several shared transcription factor binding sites in promoters of genes involved in necroptosis, one of which is LEF1. LEF1 was reported to be highly upregulated in CLL cells in comparison with normal blood B cells.
14 Sequence analysis of CYLD promoter revealed that there are two potential LEF1 responsive elements (LRE1/2, 5 0 -AACAAAG-3 0 ) upstream of the transcription initiation site. Therefore, we hypothesized that LEF1 may negatively regulate CYLD expression in CLL. Consistent with previous report, LEF1 is highly expressed in CLL cells, whereas normal B cells have very low levels of LEF1 expression, at both protein and transcription levels (Po0.001) (Figures 2b and c) . Moreover, attenuation of LEF1 expression through RNAi technology resulted in a dramatic increase in CYLD levels in CLL cells, as determined by western blot and real-time reverse transcription-PCR analysis (Po0.001) (Figures 3a and b) .
We then cloned the 2-Kb promoter sequence into a pGL3-Basic luciferase reporter plasmid. Dual-Luciferase Assays were performed on cell extracts from 293T cells co-transfected with luciferase reporter plasmid and either pLEF1 or pcDNA3.1 empty vector. As shown in Figure 4b , forced expression of LEF1 markedly decreased CYLD promoter activity compared with controls (Po0.05). Left panel of Figure 4b shows the level of LEF1 on transient pLEF1 transfection in 293T cells.
To verify the direct activity of LEF1 on CYLD transcription, AA-GG (for first LRE) and AA-CC (for second LRE on the opposite orientation) mutations that destroy the LEF1 binding were introduced into the LREs. Mutation of LRE2 abolished transcriptional repression of CYLD by LEF1, suggesting that this responsive motif is essential for the regulatory function of LEF1 on CYLD promoter activity (Figure 4b, Po0.05) . However, we failed to find any change in CYLD promoter activity when LRE1 was mutated (Figure 4b, P40.05) .
We proceeded to perform a ChIP assay in primary CLL cells to examine the recruitment of LEF1 to CYLD promoter in vivo. DNA/protein complexes were immunoprecipitated with anti-LEF1 antibody and then the purified DNA was amplified with primers flanking LRE motifs. The location of the two potential LEF1-binding sites in CYLD promoter and the primers used for ChIP assay is shown in Figure 4a . As shown in Figure 4c , LEF1 is recruited to LER2 region within the CYLD promoter in CLL cells.
Wnt signaling is an essential signal pathway that regulates cell fate determination, cell proliferation and cell polarity. The Wnt pathway leads to the stabilization of b-catenin, which associates with T-cell factors, such as LEF1 and TCF4, to activate target genes. 15, 16 In the present study, we also perform the luciferase reporter assay described in Figure 4b using expression constructs of dominant-negative LEF1 (ref. 11) (a short isoform of LEF1 that lacks the b-catenin-binding domain), b-catenin or another TCF family member TCF4. As shown in Supplementary Figure S2 , no changes in CYLD promoter activity were found following the transfection of these three constructs.
Knocking down LEF1 sensitizes CLL cells to necroptotic cell death Based on the regulatory function of LEF1 on CYLD expression and the important role of CYLD in necroptotic cell death execution, we finally examined the effect of LEF1 inhibition on CLL cell necroptosis. CLL cells were transfected with siRNA targeting LEF1 for 48 h followed by TNFa (30 ng/ml) plus zVAD (20 mM) incubation. As shown in Figure 5a , LEF1 knockdown led to a notable induction of ROS production in CLL cells compared with normal controls, as determined by CM-H2DCFDA staining and flow cytometry (Po0.05). This ROS generation induction was accompanied with a marked increase in CLL necroptotic death in response to TNFa plus zVAD treatment (Figure 5b, Po0.05) . Additionally, the ROS induction and pro-necroptotic effect were both significantly blocked by Nec-1 (Po0.05). Collectively, our results suggest that LEF1 gene silencing may restore necroptotic response of CLL cells induced by death receptor ligation.
As recent investigations showed that LEF1 siRNA transfection led to increased apoptotic cell death of CLL, 17, 18 we also determined the effect of LEF1 knockdown on CLL cell apoptosis. As shown in Supplementary Figure S3 , knocking down LEF1 resulted in a slight increase in both CLL cell-spontaneous apoptosis and apoptosis induced by TNFa (Po0.05).
DISCUSSION
Death receptor-induced necroptosis is a tightly regulated form of cell death that occurs in the absence of sufficient caspase activation. Until recently, the precise mechanisms underlying this type of cell death remain unclear. Accumulating evidence suggests that two members of the receptor-interacting serinethreonine kinase (RIP) family, RIP1 and RIP3, interact and mediate necroptosis upon death receptor ligation.
RIP1 is a multi-functional protein that has been implicated in the regulation of apoptosis as well as necroptosis. 6, 7, 19 In response to TNFa ligation, RIP1 binds to tumor necrosis factor receptor 1 through its death domain. It also associates with TNFa receptorassociated death domain and inhibitors of apoptosis proteins (IAPs) cIAP1 and cIAP2, thereby forming a complex at the plasma membrane. cIAP1 and cIAP2 direct the formation of polyubiquitin chains linked through lysine 63 (K63) of ubiquitin on RIP1. The polyubiquitination of RIP1 is essential for downstream activation of mitogen-activated protein kinases and the NF-kB pathway, which govern the expression of prosurvival genes. However, once K63-linked polyubiquitin chains of RIP1 are removed by the CYLD, RIP1 acts as a kinase promoting cell death instead of a prosurvival protein. 3,20 --24 Another member of RIP family, RIP3, has been identified as the determinant for cellular necroptosis in response to TNF family of death-inducing cytokines. 6, 8, 9 In the absence of RIP3, RIP1 interacts with caspase-8 as well as Fas-associated death domain, where it forms an apoptotic complex. Active caspase-8 cleaves RIP1 and initiates caspase cascade, which executes the extrinsic pathway of apoptosis. However, high levels of RIP3 switch apoptotic response to necroptosis, especially when caspases are inactivated. In this setting, RIP1 and RIP3 assemble a necroptotic complex containing Fas-associated death domain and caspase-8. Interdependent phosphorylation of RIP1 and RIP3 is crucial for necroptotic signaling activation. Here, RIP3 increases the activities of glycogen phosphorylase, glutamate-ammonia ligase and glutamate dehydrogenase 1. Enhanced glycogenolysis and glutaminolysis provide additional respiratory substrates and ultimately result in the overgeneration of ROS. Excess ROS may trigger mitochondrial membrane permeabilization and finally leads to necroptosis.
CYLD was originally identified as a gene mutated in familial cylindromatosis, a genetic condition that predisposes patients for the development of tumors of skin appendages, termed cylindroma. 25, 26 As a member of deubiquitinase family, CYLD regulates diverse physiological processes, ranging from immune response and inflammation to cell-cycle progression, spermatogensis and osteoclastogenesis. 25, 27, 28 Moreover, CYLD also functions as a tumor suppressor through negative control of NFkB signaling. As mentioned above, CYLD can remove ubiquitin chains of RIP1 and make it capable of forming death-inducing complex. In addition, knockdown of CYLD expression inhibits TNFa-induced necroptosis in Jurkat cells, which lack the apoptotic factor Fas-associated death domain, suggesting that CYLD may represent a key regulatory factor in the necroptotic pathway.
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CLL was thought to be a malignant disease of immature immune-incompetent B cells with minimal proliferative capacity, which accumulate because of the impaired apoptotic pathway. Given the resistance to death signal and recent investigation showing that necroptosis could be selectively activated when there is a failure of caspase activation, we surmised that CLL cells may have defects not only in apoptotic program but also in necroptotic signaling. Consistent with this hypothesis, our data showed that CLL cells failed to undergo necroptosis following treatment with TNFa or TNFa plus zVAD. Moreover, the mitochondrial generation of ROS is much lower in CLL cells compared with normal B cells in response to death receptor ligation. RIP1, RIP3, as well as CYLD were scored among the top 10 hits in two distinct siRNA screens aimed at identifying key regulators of necroptotic response induced by TNFa. 7, 8 In the present study, we detected no difference in RIP1 expression between CLL and normal B cells. However, the other two core components of necroptotic machine, RIP3 and CYLD, are markedly downregulated in CLL cells compared with healthy controls, which may at least partly explain the necroptosis resistance of this disease.
Hitomi et al. 7 recently showed that there is an enrichment of binding sites of transcription factors, including LEF1, in the promoters of genes involved in the necroptotic pathway. Data from our and other groups showed a high level of LEF1 expression in CLL. Sequence analysis of promoter region of CYLD, one of the downregulated gene identified in CLL from this study, using Transcription Element Search System revealed the presence of two potential LEF1-binding motifs upstream of the transcription initiation site. Furthermore, several findings from the current investigation indicate a regulatory role for LEF1 in the control of CYLD transcription.
LEF1 gene silencing dramatically enhanced CYLD expression in CLL. We have also shown that overexpression of LEF1 protein in 293 T cells resulted in a decrease in CYLD transcriptional activity in luciferase reporter assay and that it is mediated through LEF1 responsive element within CYLD promoter, which was further confirmed by ChIP assays. However, we failed to find any effect of LEF1 on RIP3 expression in CLL cells.
LEF1 is a downstream effector of the Wnt/b-catenin signaling pathway and was originally identified as a lymphoid-specific DNAbinding protein. 29, 30 Aberrant activation of the Wnt/b-catenin signaling pathway has been reported for CLL cells and may contribute to the defect in apoptosis that characterizes this malignancy. 31, 32 LEF1 is markedly upregulated in CLL compared with normal B cells.
14 It acts as a prosurvival factor in CLL and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. 17 Two small-molecule inhibitors of Wnt/b-catenin/LEF1 signaling (CGP049090 and PKF115-584) have been shown to induce apoptosis in CLL cells in vitro and in vivo. 18 Moreover, the diuretic agent ethacrynic acid, a Wnt inhibitor, exhibits selective toxicity to CLL cells through destabilizing LEF1/ b-catenin complex. 33 In the current study, LEF1 knockdown resulted in a marked induction of mitochondrial ROS production and a dramatic increase in percentage of necroptotic cell death in response to TNFa þ zVAD treatment, indicating it could be a critical target for pro-necroptotic therapy in CLL.
As a downstream effector of the Wnt pathway, LEF1 usually exerts its transcription regulatory effect through interaction with b-catenin. Our luciferase assay showed that b-catenin transfection had no effect on CYLD promoter activity, indicating that LEF1 inhibits CYLD transcription independent of b-catenin. Similar to our results, several reports suggested that LEF1 may function as a transcription factor when b-catenin is absent. In human tumorigenic kidney cells, LEF1 may act synergistically with src signaling to transactivate matrilysin promoter activity, through the b-catenin independent pathways. 34 LEF1, coupling with vitamin D receptor, is required for normal keratinocyte stem cell function, without interaction with b-catenin. 35 In addition, recent findings of universal nuclear overexpression of LEF1, but lack of nuclear b-catenin in the majority of CLL, strongly support our results that the regulatory function of LEF1 in this disease may be independent of b-catenin signaling. 36 In the present study, neither TCF4 nor dominant-negative LEF1 were found to have any effect on CYLD promoter activity, even though they contained the same DNA-binding motif with fulllength LEF1. Indeed, it is not an uncommon phenomenon that transcription factors of same family have differential regulatory functions. Two closely related members of hepatic nuclear-factor family, HNF1a and HNF1b, may act as transcription activator and repressor for a subset of hepatocyte-specific genes, respectively. 37 For TCF family, different LEF/TCF isoforms have been shown to vary in their ability to bind DNA. 38 In colon cancer cells, when TCF4 binds to its responsive element, transforming growth factor b dissociates b-catenin and represses the transcriptional activity of the c-myc promoter. However, transforming growth factor b loses its inhibitory effect on c-myc promoter activity when LEF1 binds to the element instead of TCF4. 39 The expression patterns of LEF1 and TCF4 are both phenotype-specific and inversely correlated in melanoma cells. LEF1 is preferentially expressed by differentiated/ proliferative phenotype cells and TCF4 by dedifferentiated/ invasive phenotype cells, suggesting that melanoma cell phenotype switching behavior is regulated by differential LEF1/TCF4 activity. 40 Taken together with our observation presented in current study, it seems that TCF-family members may regulate differential sets of gene in vivo, although they do not distinguish between the DNA-binding motifs in vitro.
Impaired cell death program has been noted as one of the hallmarks of CLL and contributes to the accumulating of malignant monoclonal B cells as well as to chemotherapy resistance. The present investigation provides the first evidence that CLL cells have defects not only in apoptotic program but also in necroptotic signaling ( Figure 6 ). Targeting the key regulators of necroptotic machine, such as LEF1, to restore this pathway may represent a novel approach for CLL treatment. interacts with RIP1 and increases the activities of glycogen phosphorylase, glutamate-ammonia ligase and glutamate dehydrogenase 1. Enhanced glycogenolysis and glutaminolysis provide additional respiratory substrates and ultimately result in the overgeneration of ROS. Excess ROS may trigger mitochondrial membrane permeabilization and finally leads to necroptosis. (b) in CLL, overexpressed LEF1 suppresses the expression of CYLD, which is essential for RIP1 deubiquitination. Moreover, the determinant for cellular necroptosis, RIP3, is also downregulated. Therefore, CLL cells fail to undergo necroptosis upon stimulation of TNFa.
